Potential genetic treatments for many generalized central nervous system (CNS) diseases require transgene expression throughout the CNS. Using oxidant stress and apoptosis caused by HIV-1 envelope gp120 as a model, we studied pan-CNS neuroprotective gene delivery into the cisterna magna (CM). Recombinant SV40 vectors carrying Cu/Zn superoxide dismutase or glutathione peroxidase were injected into rat CMs following intraperitoneal administration of mannitol. Sustained transgene expression was seen in neurons throughout the CNS. On challenge, 8 weeks later with gp120 injected into the caudate putamen, significant neuroprotection was documented. Thus, intracisternal administration of antioxidant-carrying rSV40 vectors may be useful in treating widespread CNS diseases such as HIV-1-associated neurocognitive disorders characterized by oxidative stress.
INTRODUCTION
Gene delivery to the central nervous system (CNS) is of great interest for many experimental and therapeutic applications, but presents particular challenges. Each delivery system has limitations 1-5 and the effectiveness of gene therapy for CNS diseases has so far been very limited. [6] [7] [8] Pan-CNS gene delivery to treat such widespread CNS diseases as Alzheimer's diseases and HIV-1-associated neurocognitive disorders (HAND) has been particularly problematic.
We previously demonstrated that SV40-derived vectors deliver long-term transgene expression to brain neurons and microglia, whether administered locally by intraparenchymal administration 9, 10 or diffusely by intravenous 11 or intraventricular routes, the latter with or without previous intraperitoneal injection of mannitol. 12 Intracerebral injection of rSV40s carrying antioxidant enzymes, Cu/Zn superoxide dismutase (SOD1) or glutathione peroxidase (GPx1), SV(SOD1) or SV(GPx1), into the rat caudate putamen (CP), significantly protected neurons from apoptosis caused by injection of recombinant HIV-1 envelope glycoprotein, gp120 or Tat at the same location. [12] [13] [14] Moreover, intra-CP SV40-mediated gene delivery of antioxidant enzymes largely protected against several deleterious consequences elicited by injecting gp120 into the CP. [15] [16] [17] Vector administration into the lateral ventricle, particularly if preceded by mannitol intraperitoneal, protected from intra-CP gp120-induced neurotoxicity comparably to intra-CP vector administration. 12 We studied here whether a simpler and less-traumatic approach to pan-CNS gene transfer of antioxidant enzymes into the cisterna magna (CM) can also protect against HIV-1 gp120.
RESULTS
The distribution of transgene expression was assessed in different areas of the brain, including the CP, sensory and motor cortex, hippocampus, cingulate cortex and lateral septum. Eight weeks after vector administration into the CM with previous mannitol injection, transgene expression was detected in the striatum and different areas of the brain. Many cells, most of them stained by NeuroTrace or immunostained by neuN (not shown, both neuronal markers), expressed the transgenes, SOD1 and GPx1, either in the CP (Figure 1a) , or in the cortex (Figure 1b) . Ependymal cells and cells of the choroid plexus expressed the transgenes SOD1 and GPx1 (Figure 1c) . A few microglial cells, which were identified by immunopositivity for Iba-1, expressed the transgenes (Figure 1d ). However, astrocytes, which we visualized by immunostaining for glial fibrillary acidic protein, were negative for the transgenes (Figure 1e ). Transgene expression was seen in both cerebral hemispheres. Expression of SOD1 and GPx1 was not detected after injection of the control vector, SV(BUGT), into the CM (Figure 1a) .
The distribution of transgene-expressing cells in different areas of the brain is shown in Figure 2a . We also tested transgene expression at 4 weeks after vector injection. The percentages of transgene-positive cells enumerated 4 weeks after vector administration into the CM were statistically identical to those at 8 weeks after injection, indicating that transgene expression was stable in this time frame (Figure 2b ). This is consistent with our results from intracerebral SV(SOD1) and SV(GPx1) injection, in which antioxidant transgene expression was steady over the 6-month experimental period. 9 Eight weeks after injection of SV(SOD1), SV(GPx1) or SV(BUGT) into the CM with previous admistration of mannitol, we injected an oxidant neurotoxic challenge intra-CP, 500 ng gp120. Apoptotic cells were enumerated by TUNEL one day later. Previous injection of SV(SOD1) and SV(GPx1) into the CM reduced the number of TUNEL-positive cells in the CP after gp120 challenge by B70% (SV(GPx1)) to 75% (SV(SOD1)), Po0.01 for both, compared with the control vector SV(BUGT) (Figure 3 ).
DISCUSSION
Abnormalities in oxidative metabolism have been reported in many CNS diseases. Oxidative stress probably plays a role in the development of HIV-associated neurocognitive disorder, and other neurodegenerative diseases. [18] [19] [20] A potential therapeutic strategy for treatment of HIV-1-associated neurocognitive disorders would be to limit oxidative stress-induced neurotoxicity, but requires an approach to transgene delivery that allows expression throughout the CNS. rSV40s were employed in the current study for several reasons: they transduce cells in G0 with high efficiency; they infect a wide range of cell types, particularly neurons from humans and other mammals; and they deliver genes to nondividing cells efficiently, to achieve long-term transgene expression in vitro and in vivo. 21 These vectors transduce 495% of cultured human NT2-derived neurons, primary human neurons 22, 23 and microglia 24 without detectable toxicity. We previously reported that systemic mannitol-induced hyperosmolarity can improve transgene expression after injection of SV(SOD1) and SV(GPx1) in the lateral ventricle, most likely by increasing the number of cells exposed to the administered vector. 9, 12 Few studies have reported the effects of previous injection of mannitol on CNS transgene expression; some were based on injection of adenovirus into the lateral ventricle, 25 or of adeno-associated virus vectors (AAVs) into the CM or intraparenchimally into the striatum. 26 Combining systemic mannitol-induced hyperosmolarity with injection of rAAV 27 or adenovirus 28 enhances gene expression in the rat brain and provides greater rAAV2-mediated striatal transduction than does local coinfusion. 29 Little is known about the therapeutic effects of vectors injected intra-CM. Intracisternal administration of rSV40 vectors shortly after systemic injection of mannitol resulted in a sustained transgene expression in the brain. It also decreased the number of apoptotic cells in the CP following gp120 injection into the CP. This reduction in apoptosis in the CP achieved by intra-CM vector delivery was comparable in magnitude to neuroprotection provided by localized intra-CP vector injection. 12 These data thus suggest that intracisternal administration of SV40 vectors encoding antioxidant molecules may provide efficient neuroprotection from gp120 oxidant injury in diverse CNS locations, and relatively atraumatically, that is, without necessitating penetrating the skull or brain substance. Gene transfer in the CM has previously been performed using adenoviruses [30] [31] [32] and hemagglutinin virus of Japan envelope vector. 33 However, evaluation of transgene expression in the brain parenchyma was not described in those studies, and the analyses of functional benefit from transgene expression in those animal models gave conflicting results. When AAVs were injected in the CM after administration of mannitol, broad dispersion of transgene expression was observed but only sporadic cells were transgene positive. 26 In conclusion, these present findings suggest the potential utility of intracisternal gene delivery in treating diffusely distributed CNS diseases characterized by oxidative stress.
MATERIALS AND METHODS Animals
Female Sprague-Dawley rats (200-250 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). Protocols for injecting and euthanizing animals were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee, and are consistent with Association for Assessment and Accreditation of Laboratory Animal Care standards. Animals were maintained in the animal facility according to standards and diet previously reported. 9 Antibodies Different primary antibodies were used for immunocytochemistry on tissue sections: rabbit anti-ionized calcium-binding adaptor molecule 1 (Iba1; IgG; 1:100; Waco Chemicals, Osaka, Japan), a marker of quiescent and active microglia, goat anti-glial fibrillary acidic protein (IgG; 1:100; Santa-Cruz, Santa-Cruz, CA, USA), rabbit anti-SOD1 (IgG; 1:100; AssayDesigns, Ann Arbor, MI, USA), mouse anti-GPx1 (IgG1 kappa; 1:100; Abnova, Taipei City, Taiwan) and mouse anti-NeuN (IgG1; 1:100; Chemicon International, Temecula, CA, USA). Secondary antibodies were used at 1:100 dilution: fluorescein isothiocyanate and tetramethyl rhodamine isothiocyanate-conjugated goat anti-mouse, tetramethyl rhodamine isothiocyanate-conjugated goat anti-rabbit (Sigma, Saint-Louis, MO, USA), fluorescein isothiocyanate and tetramethyl rhodamine isothiocyanate-conjugated donkey anti-mouse and anti-rabbit, fluorescein isothiocyanate-and Cy3-conjugated donkey anti-goat antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA).
Vector production
The general principles for making recombinant, Tag-deleted, replicationdefective SV40 viral vectors have been previously reported. 21 SOD1 and GPx1 transgenes were subcloned in to pT7 [RSVLTR] , in which transgene expression is controlled by the Rous sarcoma virus long terminal repeat (RSV-LTR) as a promoter. The cloned rSV40 genome was excised from its carrier protects neurons from gp120-induced apoptosis. Quantitation of apoptotic cells and protection from apoptosis by SV(SOD1) and SV(GPx1) injected into the CM 8 weeks before gp120 challenge. Apoptosis was assessed by TUNEL one day after injection of 500 ng gp120 into the CP. **Po0.01.
plasmid, gel purified and recircularized, then transfected into COS-7 cells. These cells supply in trans large T-antigen and SV40 capsid proteins, which are needed to produce recombinant replication-defective SV40 viral vectors. 34 Crude virus stocks were prepared as cell lysates, then band purified by discontinuous sucrose density gradient ultracentrifugation and titered by quantitative PCR (Stratagene, Santa Clara, CA, USA). 35 SV(BUGT), carrying the cDNA for human bilirubin-uridine 5¢-diphosphate-glucuronosyl-transferase (BUGT), has been reported and was used here as negative control vector. 36 Experimental design and sample processing Transgene expression study. A volume of 3 ml of sterile 25% mannitol in 0.9% saline per 100 g body weight was injected intraperitoneally 10 min before injection of 50 ml of SV(SOD1), SV(GPx1) or the control vector SV(BUGT) into the CM of rats (5 rats per experimental group), whose brains were harvested 4 and 8 weeks after injection.
Gp120 challenge study. To study the protective effect of SV-mediated overexpression of SOD1 and GPx1 on gp120-related apoptosis, the right CP of rats given SV(SOD1) and SV(GPx1) into the CM 8 weeks earlier (see above) was injected with 500 ng ml À1 gp120. Brains were harvested one day after the injection of 500 ng gp120 in the CP. Apoptotic cells were assessed by TUNEL assay (n¼5 in each experimental group). In all cases, controls received SV(BUGT) into the CM instead of SV(SOD1) and SV(GPx1) (n¼5).
Brains processing for morphology analysis
Brains were processed as previously reported. 9, 12 Intracisternal injection
The head of each rat was fixed in the prone position and the atlanto-occipital membrane was exposed through an occipitocerebral midline incision. 5Â10 8 IU of SV(SOD1), SV(GPx1), or the control vector SV(BUGT), in 50 ml PBS was injected into the CM using a 50 ml Hamilton syringe (22 gauge; Hamilton Co., Reno, NV, USA) after removal of 50 ml of cerebrospinal fluid. Then, the animals were placed head down for 30 min.
Immunocytochemistry
For immunofluorescence, 10 mm cryostat sections were processed for indirect immunofluorescence as previously reported. 9, 11 Mounting media contained 4¢,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) to stain nuclei. Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). As a negative control, nonimmune isotype-matched control antibody was substituted for primary antibody, and/or the primary antibody was omitted. Data presented are representative of at least three independent experiments.
Staining of neurons using NeuroTrace
NeuroTrace staining has been used as a neuronal marker in studies focusing on the characterization of neurons 37 and NT staining has been performed as previously reported. 12, 13 Combination NT+antibody staining was performed using primary and secondary antibodies staining first (see above), followed by staining with the NT fluorescent stain. All experiments were repeated three times and test and control slides were stained the same day.
Morphometric studies
Transduction was assessed for each injected brain by serial cryo sectioning of the whole brain (10 mm thick coronal sections), each slide being numbered, then by immunostaining of every fifth section for GPx1 or SOD1 and finally by using a computerized imaging system (Image-Pro Plus, MediaCybernetics, Bethesda, MD, USA). The total number (and not the number in random areas) of GPx1-or SOD1-positive cells for every fifth section was counted and summed. The final number presented for a structure was an average of the results measured in the different sections examined. This procedure already described for assessment of numbers of transgene-positive cells in the brain 9, 38 allows quantitative comparisons. We followed a similar procedure for enumerating the number of apoptotic cells after gp120 injection (the whole CPs were considered in one cryosection; at least five frontal cryosections passing through the CPs were examined). 12 
Statistical analysis
Results were expressed as average ± s.e.m. For comparison between two groups we used the Mann-Whitney test (with a two-tail P-value). Comparisons among more than two groups employed the Kruskall-Wallis test. Comparisons of two percentages were done using Fisher's exact test (with a two-sided P-value).
